New Compliance Framework for Drug Makers and Medical Device Firms

Overview of Recent Regulatory Changes

In a significant update for drug makers and medical device manufacturers, the Indian government has introduced a new mechanism aimed at addressing minor regulatory violations. This development allows companies to avoid criminal prosecution and lengthy court battles, facilitating a smoother resolution process.

The Compounding of Offences Rules, 2025

The Drugs and Cosmetics (Compounding of Offences) Rules, 2025 now permit certain offences under the Drugs and Cosmetics Act, 1940 to be settled by paying a designated compounding amount rather than facing court proceedings. This marks a pivotal shift towards compliance-based regulation while ensuring public health safeguards remain intact.

Role of the Central Drugs Standard Control Organisation (CDSCO)

The Central Drugs Standard Control Organisation (CDSCO) has issued a comprehensive guidance document detailing the eligibility criteria, timelines, and procedures for compounding offences. A designated Compounding Authority is empowered to grant immunity from prosecution in approved cases, streamlining the resolution process.

Eligibility for Compounding

Under the new rules, companies or individuals involved in the manufacture, import, sale, or distribution of drugs, cosmetics, or medical devices may apply for compounding. Applications can be submitted either before or after prosecution is initiated. Each request will be reviewed based on reports from the relevant licensing and enforcement authorities.

Conditions and Limitations

If the application for compounding is approved, the applicant must pay the stipulated compounding amount within the specified timeframe to receive immunity from prosecution. However, this protection is conditional and may be revoked if it is later determined that key information was concealed, false details were provided, or if terms were violated.

Focus on Serious Violations

Officials have stated that this new mechanism is designed to diminish litigation related to minor technical or procedural lapses, allowing regulators and courts to prioritize serious violations that could jeopardize public health, such as the distribution of spurious or unsafe drugs.

Discretionary Nature of Compounding

It is important to note that compounding is discretionary, not an entitlement. Repeat or serious offenders might not qualify for this resolution process. These rules embody the broader reforms under the Jan Vishwas framework, which aim to decriminalize minor offences while ensuring that regulatory oversight is upheld.

By employing these new guidelines, the government aims to simplify compliance and foster a more efficient regulatory environment for drug and medical device firms.